NASDAQ$INCY
Incyte Corp. · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Incyte reported financial results for Q2 2020 and provided updates on key clinical programs.
Incyte's Q2 2020 financial results showed a 16% increase in product and royalty revenues compared to the prior year, driven by growth in Jakafi net product revenues and higher product royalty revenues from Jakavi and Olumiant. The company reaffirmed its full-year 2020 financial guidance and highlighted key clinical program updates, including positive data for parsaclisib in combination with ruxolitinib in myelofibrosis patients and the FDA approval of Monjuvi for relapsed or refractory DLBCL.
- Demand for Jakafi remained robust.
- Pemazyre, Monjuvi, and Tabrecta added to the company's momentum with recent approvals.
- Positive proof-of-concept data was presented for parsaclisib in combination with ruxolitinib in myelofibrosis patients.
- The REACH3 study, evaluating ruxolitinib in patients with steroid-refractory chronic graft-versus-host disease (GVHD), met its primary endpoint.
Headline financials
Revenue & EPS history
Incyte · Revenue · Quarterly
$688M
Revenue by segment
Incyte · $775M total across 5 segments · Q3 2023
- Jakafi$636M+2.7%82.1%
- Opzelura$91.8M+140.8%11.9%
- Iclusig$27.7M+6.9%3.6%
- Pemazyre$18.9M-19.1%2.4%
- Zynyz$98—0.0%
Forward guidance
The Company has reaffirmed its full year 2020 financial guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+18.2%
Q1 2012
Best reaction
-25.8%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | +1.2% | +0.8% | |
| Q4 2025 | -8.2% | -7.3% | -15.6% | |
| Q3 2025 | -1.6% | +0.4% | +13.5% | |
| Q1 2025 | +1.5% | +5.1% | +11.0% | |
| Q4 2024 | -7.9% | -5.0% | -8.6% | |
| Q3 2024 | +12.5% | +15.9% | +14.9% | |
| Q2 2024 | -5.1% | -6.0% | -3.9% | |
| Q1 2024 | +0.7% | +2.3% | +9.0% | |
| Q4 2023 | +0.1% | +0.2% | +1.2% | |
| Q3 2023 | +4.2% | +5.2% | +4.2% | |
| Q2 2023 | +3.1% | -0.1% | +1.3% | |
| Q1 2023 | -9.7% | -11.7% | -18.4% | |
| Q4 2022 | -4.6% | -6.0% | -13.6% | |
| Q3 2022 | +3.8% | +4.0% | +8.5% | |
| Q2 2022 | -6.3% | -6.8% | -7.8% | |
| Q1 2022 | +6.1% | -1.1% | -1.9% | |
| Q4 2021 | -6.9% | -9.0% | +0.2% | |
| Q3 2021 | -3.7% | -2.1% | -3.9% | |
| Q2 2021 | -1.4% | -2.8% | -1.6% | |
| Q1 2021 | -5.0% | -3.3% | -3.1% | |
| Q4 2020 | -9.0% | -9.9% | -15.1% | |
| Q3 2020 | -8.8% | -8.9% | -8.8% | |
| Q2 2020 | -4.1% | -4.8% | -10.0% | |
| Q1 2020 | -4.9% | -5.0% | -7.1% | |
| Q4 2019 | +3.5% | +4.6% | -2.6% | |
| Q3 2019 | +4.8% | +4.7% | +17.9% | |
| Q2 2019 | +5.8% | +4.0% | +2.7% | |
| Q1 2019 | +6.1% | +11.7% | +5.9% | |
| Q4 2018 | +3.8% | +3.7% | +4.6% | |
| Q3 2018 | +2.4% | +6.5% | +2.3% | |
| Q2 2018 | -4.4% | -8.1% | +7.4% | |
| Q1 2018 | -1.4% | +0.3% | +10.2% | |
| Q4 2017 | -2.4% | -3.0% | +2.1% | |
| Q3 2017 | -5.5% | -8.0% | -13.3% | |
| Q2 2017 | -5.7% | -3.4% | +3.1% | |
| Q1 2017 | -0.6% | -2.8% | +6.7% | |
| Q4 2016 | -0.2% | -0.5% | +22.5% | |
| Q3 2016 | +0.2% | +0.7% | +14.9% | |
| Q2 2016 | -5.2% | -7.9% | -7.4% | |
| Q1 2016 | +4.0% | — | — | |
| Q4 2015 | -5.5% | — | — | |
| Q3 2015 | -2.9% | — | — | |
| Q2 2015 | +6.7% | — | — | |
| Q1 2015 | -3.3% | — | — | |
| Q4 2014 | -0.0% | — | — | |
| Q3 2014 | +15.9% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | +6.3% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q3 2013 | +4.7% | — | — | |
| Q2 2013 | +14.7% | — | — | |
| Q1 2013 | +3.3% | — | — | |
| Q4 2012 | +18.0% | — | — | |
| Q3 2012 | +6.8% | — | — | |
| Q2 2012 | -25.8% | — | — | |
| Q1 2012 | +18.2% | — | — | |
| Q4 2011 | +1.7% | — | — | |
| Q3 2010 | +0.9% | — | — | |
| Q3 2011 | +0.9% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | +6.0% | — | — | |
| Q1 2010 | +6.0% | — | — | |
| Q1 2011 | +6.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro